We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diabetes Testing Results Remotely Managed and Monitored

By LabMedica International staff writers
Posted on 28 Sep 2011
Point-of-care (POC) coordinators and laboratory managers can remotely monitor and manage HbA1c and microalbumin testing results using expanded data management solution connectivity.

The new RAPIDComm system is accessible from any computer connected to the hospital-wide network and can be customized to address the needs of different departments, users, and patients. More...
With this system, POC coordinators are able to remotely manage and maximize instrument uptime, simplify instrument control, and operator management.

Siemens Healthcare Diagnostics (Tarrytown, NY, USA) launched the RAPIDComm new data management solution Version 4.0, extending system connectivity to the company’s DCA Vantage diabetes analyzer. The data management system also enhances quality control (QC) management and documentation with automated QC result processing and customizable regulatory reports.

Now point-of-care (POC) laboratory managers are able to rely on a single, advanced user interface to remotely monitor and manage diabetes-testing results, in addition to blood gas via RAPIDSystems, and urinalysis via the CLINITEK Status Connect System. This move further integrates patient data throughout the healthcare network.

With decentralized testing, POC coordinators may be responsible for monitoring large numbers of instruments spread throughout a hospital or various hospital sites, which are operated by several hundred to several thousand operators.

“Healthcare professionals that manage POC testing in hospitals, clinics, and physician offices are increasingly looking to integrate their instruments with a data management solution to reduce transcription errors and better manage data, quality control, and operators, which ultimately helps to improve patient care,” said David Stein, PhD, CEO, Point of Care Business Unit, Siemens Healthcare Diagnostics. “A key priority for Siemens is to continue the innovation of our instruments and data management solutions to provide our POC customers with innovative and flexible connectivity options.”

Related Links:
Siemens Healthcare Diagnostics



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.